Compare Cytokinetics Inc (CYTK) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vipshop Holdings Ltd - ADR — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Vipshop Holdings Ltd - ADR trades at $12.71 (market cap $6.07B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Vipshop Holdings Ltd - ADR pays a 4.86% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Vipshop Holdings Ltd - ADR for 49 Days on average.
| CYTK | VIPS | |
|---|---|---|
Market Cap | $8.50B | $6.07B |
Volume | 2,395,556 | 3,134,219 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $20.29 |
52-Week Low | $54.76 | $12.09 |
Typical Hold Time | 19 Days | 49 Days |
Enterprise Value | $8.60B | $2.90B |
Dividend Yield | — | 4.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Vipshop (VIPS) trades at $12.72, down 0.24% on the day, with a bullish overall technical signal. The stock appears undervalued with a P/E of 4.12 and P/S of 0.41, supported by strong profitability metrics including a 9.82% net income margin and 24.44% ROE. Recent Q2 2026 earnings missed expectations, with revenue of $105.92 billion in 2025 showing a slight decline, but net income remains robust at $7.24 billion. Analyst consensus is bullish with a $16.17 price target.
The outlook for VIPS is mixed; attractive valuation and strong cash flow generation offer upside potential, but recent earnings misses and a challenging consumer environment pose near-term risks. Investor sentiment is cautiously optimistic, with 53.57% of analysts rating it a buy, though growth stagnation remains a key concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
